• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 96 -3 (77) 2025 - Djabbarova N.M., Aghababyan I.R. - SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW

96 -3 (77) 2025 - Djabbarova N.M., Aghababyan I.R. - SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW

SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW

Djabbarova N.M. - Samarkand State Medical University

Aghababyan I.R. - Samarkand State Medical University

Resume

Non-alcoholic fatty liver disease is one of the most common liver diseases in the modern world as one of the factors of metabolic syndrome. However, non-alcoholic steatohepatitis, a more active form of NAFLD characterized by liver steatosis, inflammation and swelling of hepatocytes, remains the leading cause of death from liver cirrhosis, its complications, hepatocellular carcinoma (HCC). Currently, there is no specific drug therapy for the treatment of this disease; its treatment is based on the treatment of the main risk factors. Several classes of drugs have undergone clinical trials for use as specific therapy for NAFLD; many of them are drugs used to treat type 2 diabetes (T2D), which is one of the main risk factors for the development of NAFLD. Among the most studied of them are PPAR-γ agonists, thiazolidonediones (pioglitazone), glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. In fact, the most promising class is sodium-glucose cotransporter type 2 (SGLT2) inhibitors. In our review, we focused on the use of SGLT2 inhibitors, taking into account the main pathogenetic mechanisms and modern methods of treating NAFLD.

Keywords: liver steatosis, NAFLD, NASH, insulin resistance, antidiabetic drugs, SGLT2 inhibitors.

First page

551

Last page

559

For citation:Djabbarova N.M., Aghababyan I.R. - SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW//New Day in Medicine 3(77)2025 551-559 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3. PMID: 36626630; PMCID: PMC10026948.
  2. Агабабян Ирина Рубеновна, Джаббарова Нафиса Мамасолиевна, Рофеев Мумин Шамсиевич, Назарова Зухра Шариповна, Пулатова Кристина Самвеловна (2019). Метаболический синдром как один из основных факторов развития артериальной гипертонии. Достижения науки и образования 2019;10(51):54-58.
  3. Golabi, P., Sayiner, M., Fazel, Y., Koenig, A., Henry, L., Younossi, Z. M. (2016). Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert review of gastroenterology hepatology 2016;10(1):63-71. https://doi.org/10.1586/17474124.2016.1099433
  4. Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One. 2010;5(7):e11578. https://doi.org/10.1371/journal.pone.0011578.
  5. Lee JW, Cho YK, Ryan M, Kim H, Lee SW, Chang E, et al. Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver. 2010;4(3):378-83. https://doi.org/10.5009/gnl.2010.4.3.378.
  6. Xie Y, Wang M, Zhang Y, Zhang S, Tan A, Gao Y, et al. Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. PLoS One. 2013;8(7):e67152. https://doi.org/10.1371/journal.pone.0067152
  7. Chen, C. H., Huang, M. H., Yang, J. C., Nien, C. K., Yang, C. C., Yeh, Y. H., Yueh, S. K. (2006). Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of clinical gastroenterology, 2006;40(8):745-752. https://doi.org/10.1097/00004836-200609000-00016
  8. Liu, P. J., Ma, F., Lou, H. P., Zhu, Y. N., Chen, Y. (2014). Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. Climacteric, 2014;17(6):692-699. https://doi.org/10.3109/13697137.2014.926323,
  9. Cho H. C. (2016). Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population. Gut and liver, 2016;10(1):117-125. https://doi.org/10.5009/gnl14444
  10. Statsenko M.E., Turkina S.V., Ustinova M.N., Tumarenko A.V., Sviridenko O.Yu., Sviridenko A.O. Hyperuricemia as a predictor of non-alcoholic fatty liver disease. South Russian Journal of Therapeutic Practice. 2022;3(2):19-24. (In Russ.) https://doi.org/10.21886/2712-8156-2022-3-2-19-24
  11. Zhou, M., Yang, N., Xing, X. et al. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21(43). https://doi.org/10.1186/s12876-021-01615-w
  12. Koehler, E. M., Plompen, E. P., Schouten, J. N., Hansen, B. E., Darwish Murad, S., Taimr, P., Leebeek, F. W., Hofman, A., Stricker, B. H., Castera, L., Janssen, H. L. (2016). Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology (Baltimore, Md.), 2016;63(1):138-147. https://doi.org/10.1002/hep.27981
  13. Kwok, R., Choi, K. C., Wong, G. L., Zhang, Y., Chan, H. L., Luk, A. O., Shu, S. S., Chan, A. W., Yeung, M. W., Chan, J. C., Kong, A. P., Wong, V. W. (2016). Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016;65(8):1359-1368. https://doi.org/10.1136/gutjnl-2015-309265
  14. Агабабян Ирина Рубеновна, Ким Галина Сафроновна (2023). Роль статинов в лечении неалкогольной жировой болезни печени. // Вопросы науки и образования 2023;1(166):57-69.
  15. Rubenovna, A. I., Khudayberdievich, Z. S., Abduraimovich, I. J., Mamasoliyevna, D. N. (2022). Analysis of the effect of food stereotypes on disease in liver circuit disease. Asian journal of pharmaceutical and biological research, 2022;11(2).
  16. Perumpail, B. J., Li, A. A., John, N., Sallam, S., Shah, N. D., Kwong, W., Cholankeril, G., Kim, D., Ahmed, A. (2018). The Role of Vitamin E in the Treatment of NAFLD. Diseases (Basel, Switzerland), 2018;6(4):86. https://doi.org/10.3390/diseases6040086
  17. Billington E. O., Grey A., Bolland M. J. (2015). The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia, 2015;58(10):2238-2246. https://doi.org/10.1007/s00125-015-3660-2.
  18. Liao, H. W., Saver, J. L., Wu, Y. L., Chen, T. H., Lee, M., & Ovbiagele, B. (2017). Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ open, 2017;7(1):e013927. https://doi.org/10.1136/bmjopen-2016-013927
  19. García-Compeán, D., Kumar, R., Cueto-Aguilera, Á. N. D., Maldonado-Garza, H. J., Villarreal-Pérez, J. Z. (2023). Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. Annals of hepatology, 2023;28(4):100751. https://doi.org/10.1016/j.aohep.2022.100751
  20. Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., Romero-Gomez, M. (2015). Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015;149(2):367-15. https://doi.org/10.1053/j.gastro.2015.04.005

    file

    download